Display options
Cite
Hotta S, Nakatani Y, Kambe T, et al. Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions. Exp Ther Med. 2015;10(2):535-540doi: 10.3892/etm.2015.2575.
Hotta, S., Nakatani, Y., Kambe, T., Abe, K., Masuda, Y., Utsumomiya, I., & Taguchi, K. (2015). Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions. Experimental and therapeutic medicine, 10(2), 535-540. https://doi.org/10.3892/etm.2015.2575
Hotta, Sayako, et al. "Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions." Experimental and therapeutic medicine vol. 10,2 (2015): 535-540. doi: https://doi.org/10.3892/etm.2015.2575
Hotta S, Nakatani Y, Kambe T, Abe K, Masuda Y, Utsumomiya I, Taguchi K. Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions. Exp Ther Med. 2015 Aug;10(2):535-540. doi: 10.3892/etm.2015.2575. Epub 2015 Jun 12. PMID: 26622350; PMCID: PMC4509117.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2015 Aug;10(2):535-540. doi: 10.3892/etm.2015.2575. Epub 2015 Jun 12.

Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions.

Experimental and therapeutic medicine

Sayako Hotta, Yoshihiko Nakatani, Toshie Kambe, Kenji Abe, Yutaka Masuda, Iku Utsumomiya, Kyoji Taguchi

Affiliations

  1. Department of Medicinal Pharmacology, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
  2. Department of Pharmacology, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
  3. Department of Pharmacology, School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima 963-8611, Japan.
  4. Laboratory of Clinical Pharmacy, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
  5. Department of Developmental Education, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.

PMID: 26622350 PMCID: PMC4509117 DOI: 10.3892/etm.2015.2575

Abstract

Guillain-Barré syndrome is a type of acute inflammatory neuropathy that causes ataxia and is associated with the IgG anti-GM1 antibody. However, the pathogenic role of the IgG anti-GM1 antibody and calcium channels in neuromuscular junctions (NMJs) remains unclear. Thus, the aim of the present study was to investigate the effects of the IgG anti-GM1 monoclonal antibody (mAb) on spontaneous muscle action potentials (SMAPs), and the effects of calcium channel blockers, in a rat spinal cord-muscle co-culture system. In addition, the binding of IgG anti-GM1 mAb to calcium channels was investigated in the rat hemidiaphragm. The frequency of SMAPs in the innervated muscle cells was acutely inhibited by the IgG anti-GM1 mAb; however, this effect was blocked by the N-type calcium channel blocker, ω-conotoxin GVIA (30 nM). Furthermore, the P/Q-type calcium channel blocker, ω-agatoxin IVA (10 nM), was found to partially block the IgG anti-GM1 mAb-induced inhibitory effect in the spinal cord-muscle co-culture system. Immunohistochemical analysis of the rat hemidiaphragm indicated that IgG anti-GM1 mAb binding overlapped with anti-Ca

Keywords: Guillain-Barré syndrome; IgG anti-GM1 monoclonal antibody; calcium channel; muscle action potential; neuromuscular junctions

References

  1. J Neurosci. 2000 Jan 1;20(1):59-65 - PubMed
  2. Ann Neurol. 1998 Dec;44(6):913-22 - PubMed
  3. Neurochem Res. 2002 Aug;27(7-8):637-47 - PubMed
  4. J Anat. 2014 Jan;224(1):36-44 - PubMed
  5. J Neurosci. 2006 Aug 23;26(34):8748-57 - PubMed
  6. Neurobiol Dis. 2007 Oct;28(1):113-21 - PubMed
  7. Neurochem Res. 2009 Jan;34(1):149-57 - PubMed
  8. J Neurol Sci. 2004 Oct 15;225(1-2):91-8 - PubMed
  9. J Clin Invest. 2012 Mar;122(3):1037-51 - PubMed
  10. J Biol Chem. 2004 Feb 13;279(7):5127-34 - PubMed
  11. Neurochem Res. 2002 Aug;27(7-8):697-709 - PubMed
  12. Exp Neurol. 2007 Mar;204(1):380-6 - PubMed
  13. Neuroreport. 1997 Jul 7;8(9-10):2203-7 - PubMed
  14. Neuroscience. 2004;123(1):75-85 - PubMed
  15. J Neuroimmunol. 2008 Sep 15;201-202:136-44 - PubMed
  16. Neurol Sci. 2014 Feb;35(2):205-13 - PubMed
  17. Brain Res. 2005 Feb 9;1034(1-2):62-70 - PubMed
  18. J Neuroimmunol. 2001 Mar 1;114(1-2):213-9 - PubMed
  19. J Neuroimmunol. 2001 Sep 3;119(1):114-23 - PubMed

Publication Types